{
    "nctId": "NCT02447003",
    "briefTitle": "Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)",
    "officialTitle": "A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 254,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Central Imaging Vendor (CIV) in All Cohort A Participants",
    "eligibilityCriteria": "Inclusion Criteria:\n\nFor the purposes of this study, neoadjuvant and/or adjuvant chemotherapy regimens do not count as a prior line of therapy.\n\nFor second line plus monotherapy (Parts 1 and 2):\n\n* Has received at least one systemic treatment for metastatic breast cancer\n* Has documented disease progression on or after the most recent therapy\n* Prior treatment must include an anthracycline and a taxane in the neoadjuvant, adjuvant, or metastatic setting\n\nFor first line monotherapy (Part 1):\n\n* Has received no prior systemic treatment for metastatic breast cancer\n* Has PD-L1-positive mTNBC.\n\nFor second line plus monotherapy (Part 2):\n\n- Has PD-L1 strong positive mTNBC\n\nFor all parts:\n\n* Has mTNBC confirmed by a central laboratory\n* For biomarker analysis, adequate newly obtained core or excisional biopsy of a not-previously-irradiated metastatic tumor lesion (mandatory)\n* Has measurable metastatic disease\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Female participants of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment\n* Male participants should agree to use an adequate method of contraception starting with the first dose of study treatment through 120 days after the last dose of study treatment\n* Has adequate organ function\n\nExclusion Criteria:\n\n* Is currently participating and receiving study treatment, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to study Day 1\n* Has received prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1\n* Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks prior to study Day 1\n* Has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered within at least 2 weeks prior to study Day 1\n* Has an active autoimmune disease requiring systemic treatment in past 2 years\n* Has a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment\n* Has known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer\n* Has radiographically-detectable central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis or a history of interstitial lung disease\n* Has an active infection requiring systemic therapy\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study\n* Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment\n* Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 \\[CTLA-4\\], OX-40, CD137) or has participated in Merck MK-3475 (pembrolizumab) study\n* Has a known history of human immunodeficiency virus (HIV)\n* Has known active Hepatitis B or C\n* Has received a live vaccine within 30 days of planned start of study treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}